Antivirals Market Report 2025

This Antivirals market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The antivirals market size has grown strongly in recent years. It will grow from $106.13 billion in 2024 to $114.7 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to viral disease prevalence, public health concerns, patent expirations, government initiatives.

The antivirals market size is expected to see strong growth in the next few years. It will grow to $153.67 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to emerging viral threats, global health initiatives. Major trends in the forecast period include technological advances, telemedicine and digital health, personalized medicine.

The rising incidence of influenza is expected to drive the growth of the antiviral market. Influenza, commonly known as the flu, is a highly contagious viral respiratory infection caused by influenza viruses. Antiviral medications are used to treat influenza by inhibiting the replication and spread of these viruses within the body. For instance, in October 2022, the Centers for Disease Control and Prevention (CDC), a US-based health agency, reported that during the 2021-2022 flu season, there were 9 million flu illnesses, 4 million flu-related medical visits, 100,000 flu-related hospitalizations, and 5,000 flu deaths. This increasing incidence of influenza is a key factor contributing to the growth of the antiviral market.

The growing public-private funding for life science research globally is expected to accelerate the growth of the antiviral drug therapy market. While no drugs or vaccines are currently approved for the treatment of COVID-19, several vaccines and therapies are in the pipeline awaiting approval or launch. Governments worldwide have introduced new grant funds to support research in vaccines, treatments, and diagnostics. For example, in March 2023, Gov.UK, a UK-based government agency, alongside four UK life sciences companies, received the first tranche of £277 million ($305.78 million) from the Life Sciences Innovative Manufacturing Fund. This initiative is expected to facilitate an additional £260 million ($287.01 million) in private investment, create 320 new jobs, and safeguard 199 existing ones. This follows a previous pilot fund of £75 million ($82.79 million), which secured 224 new jobs and protected 345 positions in the sector. As such, the increase in public-private funding for life science research is anticipated to boost research and development efforts, thereby driving the growth of the COVID-19 antiviral drug therapy market.

Major companies operating in the antiviral market are focusing on developing innovative treatments, such as oral antiviral medications, to improve patient compliance, enhance accessibility, reduce healthcare costs, and provide more convenient and effective options for managing viral infections. Oral antiviral treatments are taken by mouth and work by inhibiting the replication or spread of viruses in the body, helping to reduce the severity and duration of infections. For example, in May 2023, Pfizer, a US-based pharmaceutical company, announced the approval of Paxlovid by the Food and Drug Administration (FDA). This marked the first oral antiviral treatment for COVID-19 in adults. The approval is significant as it provides a new therapeutic option for managing COVID-19, especially as the pandemic transitions to an endemic phase. Paxlovid is indicated for adults with mild-to-moderate COVID-19 who are at high risk of progression to severe disease, including hospitalization or death. This treatment is expected to improve patient outcomes while offering a more convenient, oral option compared to intravenous treatments.

Major companies in the antiviral market are increasingly focused on developing advanced therapeutic solutions, such as antiviral treatments, to improve patient outcomes and reduce viral transmission. These treatments are crucial for managing viral infections and preventing complications in affected patients. For example, in August 2024, Red Queen’s Technology, a US-based pharmaceutical company, launched a new line of versatile antivirals. Apple Tree Partners invested $55 million in Red Queen Therapeutics, a biotech firm working on broad-spectrum antiviral treatments. The company targets infectious pathogens such as COVID-19 and influenza, having already advanced a COVID antiviral through Phase 1 testing and secured U.S. government funding for a pan-influenza drug. Co-founded by Harvard professor Loren Walensky, Red Queen uses stapled lipopeptides to inhibit viral fusion and block viral entry into cells.

In June 2022, Pfizer Inc., a leading US-based pharmaceutical company, completed its acquisition of ReViral Ltd. for $525 million. This strategic acquisition is part of Pfizer's effort to expand its anti-infective pipeline and strengthen its dedication to developing medications and vaccines for combating respiratory syncytial virus (RSV). ReViral Ltd., a UK-based company, specializes in the development of antiviral drugs. This acquisition enhances Pfizer's position in the fight against viral infections, particularly RSV, and represents a significant investment in the development of antiviral treatments.

Anti-viral drug therapy encompasses the use of medications to combat viral infections, including diseases like human immunodeficiency virus (HIV), hepatitis, influenza, and emerging viruses like the novel COVID-19. These drugs work by inhibiting the replication and spread of viruses rather than directly killing them. The anti-viral drug sector primarily comprises establishments engaged in the production of various classes of antiviral drugs, including DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others.

The primary categories of anti-viral drug therapy include branded and generic medications. These drugs belong to different classes tailored for specific viral infections, including HIV, hepatitis, herpes, influenza, and more. Among these, reverse-transcriptase inhibitors (RTIs) are a noteworthy class used for treating HIV and, in some cases, hepatitis B infections.

The anti-viral drug therapy market research report is one of a series of new reports that provides anti-viral drug therapy market statistics, including anti-viral drug therapy industry global market size, regional shares, competitors with an anti-viral drug therapy market share, detailed anti-viral drug therapy market segments, market trends and opportunities, and any further data you may need to thrive in the anti-viral drug therapy industry. This anti-viral drug therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the antivirals market include AbbVie Inc., Bristol-Myers-Squibb Co., Chemical Industrial & Pharmaceutical Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Ltd., Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd., AstraZeneca plc, Aurobindo Pharma Ltd., Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi-Synthélabo Ltd., Regeneron Pharmaceuticals Inc., Inovio Pharmaceuticals Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Argos Distributors Limited, AVI Biopharma International Ltd., Moderna Inc., BioNTech SE, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Genentech USA Inc., Vertex Pharmaceuticals Inc.

North America was the largest region in the anti-viral drug therapy market in 2024. The Middle East is expected to be the fastest-growing region in the antivirals market during the forecast period. The regions covered in the antivirals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antivirals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-viral drug therapy market consists of sales of amantadine and rimantadine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.